ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1437

Journal of Clinical & Experimental Pathology received 1437 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

Clinicopathological analysis of BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis

6th European Pathology Congress

Ying Guo

Fourth Military Medical University, China

Posters & Accepted Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.C1.023

Abstract
Langerhans cell histiocytosis (LCH) is a clinically and histologically heterogeneous disorder, characterized by a reactive clonal proliferation and accumulation of CD1a+/CD207+ dendritic cells in inflammatory lesions. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship between the mutation, clinical findings and differentiation status of LCH respectively, we studied 97 cases of LCH using Sanger sequencing and immunohistochemistry. The mutually exclusive BRAFV600E and MAP2K1 mutation rates were 32% and 17.5%, respectively. All MAP2K1 mutations were missense mutations without any in-frame deletions, two new recurrent missense mutations (i.e., p.E38K and p.P105S) were also found. More BRAFV600E and MAP2K1 mutations occurred in underage patients compared to adult patients and were correlated with relapse. To the differentiation related markers, the BRAF/MAP2K1-mut LCH expressed CD14 but rarely expressed CD83 or CD86 (p<0.001). On the contrary, BRAF/MAP2K1-wt LCH cells rarely expressed CD14 but expressed CD86 and some cells also expressed CD83+ (p<0.001). This indicates that the BRAF/MAP2K1-mut LCH cells had a more immature state than BRAF/MAP2K1-wt LCH cells. Moreover, we also found the BRAFV600E and MAP2K1 mutations were significantly associated with pERK expression (p<0.001). Therefore, the RAS/ RAF/MEK/ERK pathway might play a more important role in LCH in underage patients than in adult patients.
Biography

Ying Guo has completed her MD from Shanxi Medical University and PhD from Fourth Military Medical University. She is an Associate Professor of Department of Pathology of Fourth Military Medical University. She has published more than 20 international papers and 40 Chinese papers in reputed journals.

Email: guoying@fmmu.edu.cn

Top